Hemostatic state of children with type 1 diabetes
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Hyperglycemia is one of the factors responsible for the molecular alterations that modify hemostasis. The aim of this study was to determine the levels of circulating molecules that have a prothrombotic impact on the child and adolescent population with type 1 diabetes mellitus. Methods: There were 35 patients with type 1 diabetes mellitus (11.0±2.5 years of age and a median 3.7±2.0 years of the disease) with no vascular complications and 20 healthy controls with similar age, sex, and body mass index included in the study. The evaluated parameters were fibrinogen, plasminogen activator inhibitor-1 (PAI-1), von Willebrand factor antigen, and standard coagulation tests (platelet count, prothrombin time, and activated partial thromboplastin time). Glycemic control was evaluated by hemoglobin A1c and fasting blood glucose tests, and the presence of retinopathy and nephropathy was ruled out. The data obtained were analyzed by IBM SPSS Statistics ver. 20.0 and expressed as mean±standard deviation. The Pearson correlation coefficient was applied to investigate correlations between variables. Results: Diabetic patients showed significantly higher levels of fibrinogen (308±66 mg/dL vs. 246±18 mg/dL, P=0.0001), PAI-1 (41.6±12 ng/mL vs. 11.7±1.0 ng/mL, P=0.0001), and von Willebrand factor antigen (284%±55% vs. 121%±19%, P=0.0001). However, standard coagulation tests did not show differences between the 2 groups. PAI-1 was correlated with glycemia, hemoglobin A1c, fibrinogen, and von Willebrand factor antigen. Conclusion: Elevated levels of fibrinogen, PAI-1, and von Willebrand factor antigen were found in the pediatric and adolescent population with type 1 diabetes mellitus, which suggests a prothrombotic state.
Abstract
Purpose: Hyperglycemia is one of the factors responsible for the molecular alterations that modify hemostasis. The aim of this study was to determine the levels of circulating molecules that have a prothrombotic impact on the child and adolescent population with type 1 diabetes mellitus. Methods: There were 35 patients with type 1 diabetes mellitus (11.0±2.5 years of age and a median 3.7±2.0 years of the disease) with no vascular complications and 20 healthy controls with similar age, sex, and body mass index included in the study. The evaluated parameters were fibrinogen, plasminogen activator inhibitor-1 (PAI-1), von Willebrand factor antigen, and standard coagulation tests (platelet count, prothrombin time, and activated partial thromboplastin time). Glycemic control was evaluated by hemoglobin A1c and fasting blood glucose tests, and the presence of retinopathy and nephropathy was ruled out. The data obtained were analyzed by IBM SPSS Statistics ver. 20.0 and expressed as mean±standard deviation. The Pearson correlation coefficient was applied to investigate correlations between variables. Results: Diabetic patients showed significantly higher levels of fibrinogen (308±66 mg/dL vs. 246±18 mg/dL, P=0.0001), PAI-1 (41.6±12 ng/mL vs. 11.7±1.0 ng/mL, P=0.0001), and von Willebrand factor antigen (284%±55% vs. 121%±19%, P=0.0001). However, standard coagulation tests did not show differences between the 2 groups. PAI-1 was correlated with glycemia, hemoglobin A1c, fibrinogen, and von Willebrand factor antigen. Conclusion: Elevated levels of fibrinogen, PAI-1, and von Willebrand factor antigen were found in the pediatric and adolescent population with type 1 diabetes mellitus, which suggests a prothrombotic state.
참고문헌 (35)
- Vehik K, "The changing epidemiology of type 1diabetes : why is it going through the roof", Diabetes Metab Res Rev, 27, pp.3~13 (2011)
- Targher G, "Hemostatic disorders in type 1 diabetes mellitus", Semin Thromb Hemost, 37, pp.58~65 (2011)
- Rodrigues TC, "Higher fibrinogen levels predict progression of coronary artery calcification in adults with type 1diabetes", Atherosclerosis, 210, pp.671~673 (2010)
- Alessi MC, "Plasminogen activator inhibitor-1, adipose tissue and insulin resistance", Curr Opin Lipidol, 18, pp.240~245 (2007)
- Cesari M, "Plasminogen activator inhibitor-1(PAI-1) : a key factor linking fibrinolysis and age-related subclinical and clinical conditions", Cardiovasc Ther, 28, pp.72~91 (2010)
- Gragnano F, "The role of von Willebrand Factor in vascular inflammation : from pathogenesis to targeted therapy", Mediators Inflamm, 2017, pp.5620314~ (2017)
- Frankel DS, "Von Willebrand Factor, type 2diabetes mellitus, and risk of cardiovascular disease : The Framingham Offspring Study", Circulation, 118, pp.2533~2539 (2008)
- Madan R, "Coagulation profile in diabetes and its association with diabetic microvascular complications", J Assoc Physicians India, 58, pp.481~484 (2010)
- Adly AA, "Plasminogen activator inhibitor-1(PAI-1)in children and adolescents with type 1 diabetes mellitus : relation to diabetic microvascular complications and carotid intima media thickness", J Diabetes Complications, 28, pp.340~347 (2014)
- Carrizo T del R, "Soluble E-Selectin in children and adolescents with type 1 diabetes", Medicina(B Aires), 68, pp.193~197 (2008)
- Rabago Rodríguez R, "Carotid intima-media thickness in pediatric type 1 diabetic patients", Diabetes Care, 30, pp.2599~2602 (2007)
- Babar GS, "Impaired endothelial function in preadolescent children with type 1 diabetes", Diabetes Care, 34, pp.681~685 (2011)
- American Diabetes Association, "13. Children and adolescents: standards of medical care in diabetes-2020", Diabetes Care, 43(Suppl 1), pp.S163~S182 (2020)
- Romano M, "Endothelial perturbation in children and adolescents with type 1 diabetes : association with markers of the inflammatory reaction", Diabetes Care, 24, pp.1674~1678 (2001)
- Sobczak A, "Coagulatory defects in type-1 and type-2 diabetes", Int J Mol Sci, 20, pp.6345~ (2019)
- Carmassi F, "Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus", Thromb Res, 67, pp.643~654 (1992)
- Binay C, "Evaluation of coagulation profile in children with type1diabetes mellitus using rotational thromboelastometry", Indian J Hematol Blood Transfus, 33, pp.574~580 (2017)
- Blann AD, "Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 diabetes mellitus", Diabet Med, 15, pp.634~642 (1998)
- Sapkota B, "Association of activated partial thromboplastin time and fibrinogen level in patients with type II diabetes mellitus", BMC Res Notes, 6, pp.485~ (2013)
- Kim HK, "High coagulation factor levels and low protein C levels contribute to enhanced thrombin generation in patients with diabetes who do not have macrovascular complications", J Diabetes Complications, 28, pp.365~369 (2014)
- Targher G, "Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in type 1 diabetic patients without clinically manifest macroangiopathy", Diabet Med, 22, pp.999~1004 (2005)
- Behl T, "Role of altered coagulation-fibrinolytic system in the pathophysiology of diabetic retinopathy", Vascul Pharmacol, 92, pp.1~5 (2017)
- Lemkes BA, "Hyperglycemia : a prothrombotic factor", J Thromb Haemost, 8, pp.1663~1669 (2010)
- Milne R, "Advanced glycation end products and diabetic retinopathy", Amino Acids, 44, pp.1397~1407 (2013)
- Geraldes P, "Activation of protein kinase C isoforms and its impact on diabetic complications", Circ Res, 106, pp.1319~1331 (2010)
- Daniels M, "Factors associated with microalbuminuria in 7, 549 children and adolescents with type 1 diabetes in the T1D Exchange clinic registry", Diabetes Care, 36, pp.2639~2645 (2013)
- Mohammad HA, "Predictors of glycemic control in children with Type 1 diabetes mellitus in Assiut-Egypt", Indian J Endocrinol Metab, 16, pp.796~802 (2012)
- Dutta T, "Impact of long-term poor and good glycemic control on metabolomics alterations in type 1 diabetic people", J Clin Endocrinol Metab, 101, pp.1023~1033 (2016)
- Franco MM, "Glycemic control and the production of cytokines in diabetic patients with chronic periodontal disease", RGO-Revista Gaúcha de Odontologia, 63, pp.432~438 (2015)
- Kırmızıbekmez H, "Detection of vascular risk markers in children and adolescents with type 1 diabetes", J Pediatr Endocrinol Metab, 27, pp.87~92 (2014)
- Zhao Y, "Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values", PLoS One, 6, pp.e16470~ (2011)
- Sarkisova K, "Effect of HbA1c and hyperglycemia on hemostasis in patients with type 1diabetes", Endocrine Abstracts, 63, pp.GP218~ (2019)
- Zorio E, "Fibrinolysis : the key to new pathogenetic mechanisms", Curr Med Chem, 15, pp.923~929 (2008)
- Singh NK, "Elevated plasminogen activator inhibitor type-1(PAI-1)as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome", Rheumatol Int, 33, pp.2331~2336 (2013)
- Yarmolinsky J, "Plasminogen activator inhibitor-1 and type 2 diabetes : a systematic review and meta-analysis of observational studies", Sci Rep, 6, pp.17714~ (2016)